Sunshine Biopharma's (OTCBB: SBFM.ob) Anti-Cancer Compound Found to be a Strong Top2 Inhibitor

Tallahassee, FL 10/25/11 (PennyPayDay) --According to the American Cancer Society, there are over 11 million Americans living with cancer, and with approximately 1.5 million new cases being diagnosed each year in the U.S. Virtually all cancers are either aggressive at the onset or become aggressive overtime. The two genes associated with aggressive forms of cancer are Her2 and Top2. Currently, Herceptin (R)*, with sales of $1,8 Billion per year, is an effective treatment for Her2 positive patients. However, there are no effective therapies on the market that target Top 2. Inhibition of Top2 activity is essential in the fight against aggressive types of cancer, including multi-resistant breast cancer.

Sunshine Biopharma Inc. (OTCBB: SBFM.ob) is a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. Recently, it announced the completion of a study in which the ability of Adva-27a, its lead compound, to inhibit the activity of Top2 was measured directly. In multi-drug resistant breast cancer, the gene that encodes Top2 has been found to be amplified as much as 10-fold thereby allowing the cancer cells to make tens of thousands of Top2 molecules. Effective inhibition of Top2 activity would arrest the ability of cancer cells to multiply rapidly and spread.

In the present study the ability of Adva-27a to inhibit Topoisomerase II was measured in a concentration dependent fashion using highly purified, human Topoisomerase II alpha and concatenated plasmid DNA as a substrate. The results showed that Adva-27a is an excellent inhibitor of Topoisomerase II. Inhibition of 50% of Topoisomerase II activity (IC50) took place at a concentration of only 13.7 micromolar Adva-27a.

"An IC50 of 13.7 micromolar indicates that Adva-27a is an excellent inhibitor of Topoisomerase II", said Dr. Steve N. Slilaty, Sunshine's President and CEO. "Compounds displaying IC50's in the 75 to 100 micromolar range cannot be developed into effective drugs as the amounts which would have to be administered to patients would be too toxic. We are delighted to find that our compound has such low IC50. This is a significant milestone in our continued development of Adva-27a", he added.

PennyPayDay Disclaimer

Distributed by Viestly